U.S. pharmaceutical giant Pfizer (PFE) has maintained its sales forecasts for its COVID-19
antiviral pill called “Paxlovid.”
The company said it expects $22 billion U.S. in Paxlovid sales this year. It also reiterated its
forecast of $32 billion in sales from sales of its COVID-19 vaccines.
At the request of the U.S. Securities and Exchange Commission (SEC), several American drug
companies have adjusted their forecasts to include expenses from milestone payments and
acquisitions.
Pfizer said it now expects full year adjusted profit of $6.25 U.S. to $6.45 U.S. per share, below
its previous forecast of $6.35 U.S. to $6.55 U.S, mostly due to the impact of those expenses.
Pfizer stock is down 15% year to date at $48.34 U.S. per share.
